CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing treatments for Autism Spectrum Disorder (ASD) by targeting specific genetic causes. It utilizes patient-derived neurons to identify effective compounds that can mitigate ASD symptoms, aiming for preclinical validation of these treatments.
ASD is a very prevalent neurodevelopmental condition affecting more than 1% individuals, and represents a major unmet medical need since no effective treatment is available.
Despite the phenotypic convergence of its core symptoms (impaired language, restriction in sociability and stereotypies, invariably coupled to anxiety and often associated to varying degrees of intellectual disability), ASD is genetically highly heterogeneous, with hundreds of bona fide causative genetic lesions.
This geneti…
UNIVERSITA DEGLI STUDI DI MILANO
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Italy, Milano
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
